Tourmaline Bio Announces Positive Phase 2 Trial Results

Tourmaline Bio ( (TRML) ) has provided an update.

On May 20, 2025, Tourmaline Bio announced positive topline results from its ongoing Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. The trial demonstrated significant reductions in hs-CRP levels with pacibekitug, marking it as the first IL-6 inhibitor to achieve such results with quarterly dosing. The safety profile of pacibekitug was comparable to placebo, supporting its advancement into potential Phase 3 trials for cardiovascular outcomes and a planned Phase 2 trial for abdominal aortic aneurysm.

The most recent analyst rating on (TRML) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Tourmaline Bio stock, see the TRML Stock Forecast page.

Spark’s Take on TRML Stock

According to Spark, TipRanks’ AI Analyst, TRML is a Neutral.

Tourmaline Bio’s overall stock score reflects substantial financial and profitability challenges. While the technical indicators suggest some positive momentum, the negative P/E ratio and lack of dividend yield indicate valuation concerns. The strong equity position is a positive, but is overshadowed by the company’s significant cash flow issues and lack of revenue growth.

To see Spark’s full report on TRML stock, click here.

More about Tourmaline Bio

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for life-altering immune and inflammatory diseases.

Average Trading Volume: 329,140

Technical Sentiment Signal: Sell

Current Market Cap: $427.2M

For detailed information about TRML stock, go to TipRanks’ Stock Analysis page.